Protective effect of meloxicam-loaded nanocapsules against amyloid-β peptide-induced damage in mice

Behavioural Brain Research

Volumn 230, Issue 1, 2012, Pages 100-107

  Ianiski, Francine R ^a   Alves, Catiane B ^a   Souza, Ana Cristina G ^b   Pinton, Simone ^b   Roman, Silvane S ^b   Rhoden, Cristiano R B ^a   Alves, Marta P ^a   Luchese, Cristiane ^a  

^a CENTRO UNIVERSITÁRIO FRANCISCANO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Alzheimer's disease; Amyloid ; Meloxicam; Nanocapsules

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CATALASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; MELOXICAM; NANOCAPSULE; SUPEROXIDE DISMUTASE; THIOL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; LEARNING; MALE; MAZE TEST; MEMORY; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PASSIVE AVOIDANCE; PRIORITY JOURNAL;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; CATALASE; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; LEARNING DISORDERS; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; NANOCAPSULES; PEPTIDE FRAGMENTS; SUPEROXIDE DISMUTASE; THIAZINES; THIAZOLES; TIME FACTORS;

EID: 84857335727     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.01.055     Document Type: Article

References (60)

1. Blennow K., Leon M., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
2. Yan J.H., Rountree S., Massman P., Doody R.S., Li H. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. J Psychiatr Res 2008, 42:1203-1212.
3. Ito K., Ahadieh S., Corrigan B., French J., Fullerton T., Tensfeldt T. Disease progression meta-analysis model in Alzheimer's disease. Alzheimer's Dement 2010, 6:39-53.
4. Avramovich Y., Amit T., Youdim M.B.H. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. Am Soc Biochem Mol Biol 2002, 277:31466-31473.
5. Haass C., De Strooper B. The presenilins in Alzheimer's disease: proteolysis holds the key. Science 1999, 286:916-919.
6. Glenner G.G., Eanes E.D., Wiley C.A. Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. Biochem Biophys Res Commun 1988, 155:608-614.
7. Moore A.H., O'banion K. Neuroinflammtion and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Deliver Rev 2002, 54:1627-1656.
8. Galimberti D., Schoonemboom N., Scarpini E., Scheltens P. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol 2003, 53:547-548.
9. Medeiros R., Prediger R.D.S., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., et al. Connecting TNF-α signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid β protein. J Neurosci 2007, 27:5394-5404.
10. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 2000, 130:184-208.
11. Butterfield D.A., Reed T.T., Perluigi M., De Marco C., Coccia R., Keller J.N., et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 2007, 1148:243-324.
12. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997, 23:134-147.
13. Ah Y., Choi J., Choi Y., Ki H., Bae J. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. Int J Pharm 2010, 385:12-19.
14. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003, 24:96-102.
15. Bernardi A., Frozza R.L., Horn A.P., Campos M.M., Calixto J.B., Salbego C., et al. Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. Neurochem Int 2010, 57:629-636.
16. Carvey P.M., Hendey B., Monahan A.J. The blood-brain in neurodegenerative disease: a rhetorical perspective. J Neurochem 2009, 111:291-314.
17. Rieux A., Fievez V., Garinot M., Schneider Y.J., Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006, 116:1-27.
18. Faraji A.H., Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009, 17:2950-2962.
19. Guterres S.S., Muller C.R., Michalowski C.B., Pohlmann A.R., Dalla-Costa T. Gastro-intestinal tolerance following oral administration of spray-dried diclofenac-loaded nanocapsules and nanospheres. STP Pharma Sci 2001, 11:229-233.
20. Fessi H, Puisieux F, Devissaguet JP. Procede de preparation des systemes collidaux dispersibles d'une substance sous forme de nanocapsules. European Patent, 0274961 A1, 1988.
21. Wang H.H., Chou C.J., Liao J.F., Chen C.F. Dehydroevodiamine attenuates b-amyloid peptide-induced amnesia in mice. Eur J Pharmacol 2001, 413:221-225.
22. Haley T.J., Mccormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 1957, 12:12-15.
23. Morris R.G. Development of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
24. Sakaguchi M., Koseki M., Wakamatsu M., Matsumura E. Effects of systemic administration of beta-casomorphin-5 on learning and memory in mice. Eur J Pharmacol 2006, 530:81-87.
25. Walsh R.N., Cummins R.A. The open-field test: a critical review. Psychol Bull 1976, 83:482-504.
26. Loetchutinat C., Kothan S., Dechsupa S., Meesungnoen J., Jay-Gerin J., Mankhetkorn S. Spectrofluorometric determination of intracellular levels of reactive oxygen species in drug-sensitive and drug-resistant cancer cells using the 2',7'-dichlorofluorescein diacetate assay. Radiat Phys Chem 2005, 72:323-331.
27. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
28. Misra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and simple assay for superoxide dismutase. J Biol Chem 1972, 247:3170-3175.
29. Aebi H. Catalase in vitro. Methods Enzymol 1984, 105:121-126.
30. Wendel A. Glutathione peroxidase. Methods Enzymol 1981, 77:325-333.
31. Calberg I., Mannervik B. Glutathione reductase. Methods Enzymol 1985, 113:484-490.
32. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974, 249:7130-7139.
33. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 1976, 72:248-254.
34. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
35. Yamaguchi Y., Kawashima S. Effects of amyloid-β-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol 2001, 412:265-272.
36. Um M.Y., Choi W.H., Aan J.Y., Kim S.R., Ha T.Y. Protective effect of Polygonum multiflorum Thunb on amyloid β-peptide 25-35 induced cognitive deficits in mice. J Ethnopharmacol 2006, 104:144-148.
37. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered 13-amyloid peptides involves cholinergic dysfunction. Brain Res 1996, 706:181-193.
38. Morgan C., Colombres M., Nuñez M.T., Inestrosa N.C. Structure and function of amyloid in Alzheimer's disease. Prog Neurobiol 2004, 74:323-349.
39. Markesbery W.R., Carney J.M. Oxidative alternation in Alzheimer's disease. Brain Pathol 1999, 9:133-146.
40. Lyras L., Cairns N.J., Jenner A., Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem 1997, 68:2061-2069.
41. in t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001, 345:1515-1521.
42. Szekely C.A., Zandi P.P. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol Disord Drug Targets 2010, 9:132-139.
43. Vlad S.C., Miller D.R., Kowall N.W., Felson D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008, 70:1672-1677.
44. Albengres E., Pinquier J.L., Riant P., Bree F., Urien S., Barre J., et al. Pharmacological criteria for risk-benefit evaluation of NSAIDs. Scand J Rheumatol 1988, 17(s73):3-15.
45. Modi G., Oillay V., Choonara Y.E., Ndesendo V.M.K., du Toit L.C., Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009, 88:272-285.
46. Bernardi A., Braganhol E., Jager E., Figueiro F., Edelweiss M.I., Pohlmann A.R., et al. Indometacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 2009, 281:53-63.
47. Benvegnu D.M., Barcelos R.C., Boufleur N., Reckziegel P., Pase C.S., Ourique A.F., et al. Haloperidol-loaded polysorbate-coated polymeric nanocápsulas increase its efficacy in the antipsychotic treatment in rats. Eur J Pharm Biopharm 2011, 77:332-336.
48. Wohlfart S., Khalansky A.S., Gelperina S., Begley D., Kreuter J. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Control Release 2011, 154:103-107.
49. Wen Z., Yan Z., Hu K., Pang Z., Cheng X., Guo L., et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and harmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 2011, 151:131-138.
50. Ikota H., Kinjo S., Yokoo H., Nakazato Y. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 2006, 111:475-482.
51. 14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target 2006, 14:97-105.
52. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002, 10:317-325.
53. Lockman P.R., Oyewumi M.O., Koziara J.M., Roder K.E., Mumper R.J., Allen D.D. Brain uptake of thiamine-coated nanoparticles. J Control Release 2003, 93:271-282.
54. Vaalburg W., Hendrikse N.H., Elsinga P.H., Bart J., van Waarde A. P-glycoprotein activity and biological response. Toxicol Appl Pharm 2005, 207:257-260.
55. El-Shabouri M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporine-A. Int J Pharm 2002, 249:101-108.
56. Bhardwaj V., Hariharan S., Bala I., Lamprecht A., Kumar N., Panchagnula R., et al. Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J Biomed Nanotechnol 2005, 1:235-258.
57. Khachane P., Date A.A., Nagarsenker M.S. Positively charged polymeric nanopaticles: application in improving therapeutic efficacy of meloxicam after oral administration. Pharmazie 2011, 66:334-338.
58. Heneka M.T., O'banion M.K. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007, 184:69-91.
59. Van Antwerpen P., Neve J. In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. Eur J Pharmacol 2004, 496:55-61.
60. Arafa H.M.M., Abdel-Wahab M.H., El-Shafeey M.F., Badary O.A., Hamada F.M.A. Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. Eur J Pharmacol 2007, 564:181-189.